Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Phase 1

Completed

• Conditions: Neoplasms

• Registration Number: NCT00265057
• Lead Sponsor: Adherex Technologies, Inc.

Brief Summary

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06
• Study First Submitted: 2005-12-13
• Study First Submitted QC: 2005-12-13
• Study First Posted: 2005-12-14
• Study Completion: 2008-01
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-27
• Last Update Posted: 2010-12-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (3)

Istituto Nazionale per lo Studio e la Cura dei Tumori; 🇮🇹 Milan, Italy

Instituto Europeo di Oncologia; 🇮🇹 Milan, Italy

Istituto Oncologico della Svizzera Italiana; 🇨🇭 Bellinzona, Switzerland